U3 Pharma achieves preclinical proof of concept for U3-1287 (AMG 888)
HER3 antibody a promising novel first-in-class HER family inhibitor
15-Apr-2008 -
U3 Pharma announced that preclinical proof-of-concept has been established for its lead product U3-1287 (AMG 888), the first fully human anti-HER3 monoclonal antibody (mAb). In vitro and in vivo studies of U3-1287 (AMG 888), which is being developed in partnership with Amgen, demonstrate that the ...
Amgen
antibodies
cell lines
+5